{"id":238045,"date":"2026-05-30T06:04:04","date_gmt":"2026-05-30T11:04:04","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/05\/teclistamab-extends-remission-in-relapsed-myeloma-with-70-progression-free-at-18-months"},"modified":"2026-05-30T06:04:04","modified_gmt":"2026-05-30T11:04:04","slug":"teclistamab-extends-remission-in-relapsed-myeloma-with-70-progression-free-at-18-months","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/05\/teclistamab-extends-remission-in-relapsed-myeloma-with-70-progression-free-at-18-months","title":{"rendered":"Teclistamab extends remission in relapsed myeloma, with 70% progression-free at 18 months"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/teclistamab-extends-remission-in-relapsed-myeloma-with-70-progression-free-at-18-months.jpg\"><\/a><\/p>\n<p>Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in remission far longer than those receiving standard therapies, according to results from a major international Phase III clinical trial published in <i>The <i>New England Journal of Medicine<\/i><\/i> and presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.<\/p>\n<p>The study, led by senior author C. Ola Landgren, M.D., Ph.D., found nearly 70% of patients receiving teclistamab had no disease progression after 18 months\u2014compared with about 27% of patients receiving standard treatments\u2014while nearly two-thirds achieved complete remission, including many with no detectable cancer on highly sensitive testing.<\/p>\n<p>Landgren is chief of the Sylvester Myeloma Institute at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in remission far longer than those receiving standard therapies, according to results from a major international Phase III clinical trial published in The New England Journal of Medicine and presented at the 2026 American Society of Clinical Oncology (ASCO) Annual [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-238045","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/238045","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=238045"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/238045\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=238045"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=238045"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=238045"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}